New fund for Australasia’s biggest life sciences VC firm

5 June 2024

Brandon Capital, Australasia’s leading life sciences venture capital (VC) firm, has announced the launch of its sixth fund.

With an initial close at A$270 million ($180 million), Brandon Capital Fund VI will support the growth of Australian and New Zealand life sciences start-ups, invest in scale-ups, and expand Brandon Capital's international presence, particularly in the UK, Europe, and the USA.

Fund VI is backed by existing limited partner (LP) investors, including Australian pension funds, and new investors. The fund remains open, with ongoing discussions with potential investors both locally and internationally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK